Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Legal Issues Advertising, Marketing & Sales Commercial

Ethicon Wins Preliminary Injunction In Counterfeit Device Suit

  • News

Executive Summary

The J&J subsidiary says the distributor sold at least 7,000 forged, expired or contaminated Ethicon devices.

You may also be interested in...



Johnson & Johnson To Collect $6M In Counterfeit Device Case

An Illinois vendor reportedly sold at least 7,000 expired and counterfeit Ethicon surgical tools.

J&J Wins Injunction Against Alleged Counterfeit Product Distributor

Medical supplies distributor eSutures is facing a federal injunction over allegations the vendor sold counterfeit surgical supplies purportedly made by Johnson & Johnson unit Ethicon.

Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.

Table

View full table

Topics

Tags:
Legal Issues Advertising, Marketing & Sales Commercial
Latest Headlines

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Second EU MDR Notified Body Designated In France

Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217

See All
UsernamePublicRestriction

Register

MT142857

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By